Search:
		PML: What MS-Treating Clinicians Need To Know Sponsored by the Postgraduate Institute for Medicine Release date: December 2006 Expiration date: December 2007 Estimated time to complete activity: 1 hour This educational program is supported through an educational grant from Biogen IDEC and Elan Pharmaceuticals Inc. The reporting of progressive multifocal leukoencephalopathy (PML) in association with natalizumab therapy, leading to the temporary withdrawal from the market of this agent, makes education regarding this relatively unusual disease critical. This program will outline the current state of knowledge of PML and discuss the disease itself (both the primary disease and the phenomenon occurring secondary to reversible causes). The clinical manifestations of PML vs. MS, the association of PML with natalizumab and other immune modulators/suppressants, and the fact that there is no current treatment—save immune restoration—will also be covered. Processor Speed: 1.4 GHz P3 Memory: 256 MB RAM (20 MB Available) Operating Systems Supported: Windows 2000 / XP Browsers Supported: Internet Explorer 5.5 or greater and Mozilla Firefox Additional Requirements: Flash player 8.0 or greater 800x600 Resolution or Higher with 32-bit color Connection Speed: 128 Kbps or better Adobe Reader 6.0 or greater. Click here to review the complete CME information. Produced by Healthology Inc. © 2006
	Resources  |  About Us  |  Contact Us  |  Privacy Policy  |  Disclaimer  |  Editorial & Sponsorship Policy  |  Terms of Use Search: